Cat.No. : CSC-RO0126 Host Cell: Ba/F3
Size: >1x10^6 frozen cells/vial, 1 mL Stability: Stable in culture over a minimum of 10 passages
| Cat. No. | CSC-RO0126 |
| Description | Ba/F3-EGFR cell line is a stably transfected cell line which expresses human epidermal growth factor receptor (EGFR). |
| Target Gene | EGFR |
| Gene Species | Homo sapiens (Human) |
| Host Cell | Ba/F3 |
| Host Cell Species | Mus musculus (Mouse) |
| Stability | Stable in culture over a minimum of 10 passages |
| Application | Drug screening and biological assays |
| Growth Conditions | 37 °C, 5% CO2 |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Size | >1x10^6 frozen cells/vial, 1 mL |
| Biosafety Level | 2 |
| Thawing & Subculturing Instructions | 1. Thaw cells by gently swirling in a 37°C water bath. To limit contamination, do not submerge the O-ring and cap. 2. When cells are ~70% thawed (~1 min), transfer the vial into a biosafety cabinet, and wipe the surface with 70% ethanol. Allow tube to dry completely. 3. Transfer the cells gently into a 15 mL conical tube containing 10 mL of pre-warmed culture medium (without antibiotic selection marker). Centrifuge cells at ~125 x g for 5~7 min. 4. Remove supernatant without disturbing the pellet, and resuspend cells in 1 mL culture medium (without antibiotic selection marker). Transfer cells to a 6-well plate containing ~2 mL pre-warmed growth medium (without antibiotic selection marker) or a T25 flask containing 5 mL pre-warmed culture medium (without antibiotic selection marker). 5. Incubate the culture at 37°C with 5% CO2. 6. Subculture: split saturated culture 1:4 ~ 1:6 every 3 days; seed out at about 1~3 x 10^5 cells/mL. |
| Growth Properties | Suspension, round |
| Freeze Medium | Frozen with 70% medium, 20% FBS, 10% DMSO |
| Freezing Instructions | Cells are recommended to generate additional frozen stocks at early passages. Frozen stocks should be preserved in a designated cryopreservation medium or in 70% RPMI 1640 + 20% FBS + 10% DMSO (without antibiotic selection marker). 1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO, without antibiotic selection marker) fresh immediately before use. 2. Keep the freezing medium on ice and label cryovials. 3. Transfer cells to a sterile, conical centrifuge tube, and count the cells. 4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium. 5. Resuspend the cells at a density of at least 3 x10^6 cells/ml in chilled freezing medium. 6. Aliquot 1 ml of the cell suspension into each cryovial. 7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer. 8. Transfer vials to liquid nitrogen for long-term storage. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Cancers with epidermal growth factor receptor (EGFR) mutations are difficult to treat owing to acquired resistance to targeted therapy. The C797S mutation makes cancers resistant to osimertinib, a third-generation EGFR TKI. A novel family of EGFR TKIs generated from the marine alkaloid lamellarin N was studied, especially lamellarin 14. This compound demonstrated effectiveness against the C797S mutant, showcasing its potential to overcome resistance associated with existing therapies. In studies, Ba/F3 cells expressing triple-mutant EGFR showed sensitivity to lamellarin 14, indicating its promise in targeted cancer treatment.
Figure 1. The researchers established Ba/F3 cells expressing TKI-resistant mutant EGFRs, specifically del ex19/T790M and del ex19/T790M/C797S, to assess the effects of lamellarin 14. (Nishiya N, et al., 2021)
Creative Biogene's Human EGFR Stable Cell Line-Ba/F3 is particularly relevant in this context. This cell line is designed to facilitate the study of EGFR mutations and evaluate the efficacy of novel inhibitors like lamellarin 14. It enables researchers to analyze drug responses in a controlled environment, promoting insights into resistance mechanisms and therapeutic efficacy.
A: The EGFR (Epidermal Growth Factor Receptor) gene encodes a protein that is a key player in cell growth, proliferation, and survival. EGFR is overexpressed or mutated in various cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, and glioblastoma. These alterations lead to uncontrolled cell growth and can drive tumor progression and metastasis.
A: EGFR contributes to cancer development and progression by activating signaling pathways that promote cell growth, invasion, and angiogenesis. When overexpressed or mutated, EGFR can become constitutively active, leading to unregulated cell proliferation and resistance to apoptosis. This dysregulation can disrupt normal tissue architecture and facilitate the spread of cancer.
A: Targeting the EGFR gene and its protein product is a central strategy in the treatment of certain cancers. Targeted therapies, such as monoclonal antibodies (e.g., cetuximab) and tyrosine kinase inhibitors (e.g., erlotinib), can block the function of EGFR, slowing or stopping the progression of cancer. These treatments are particularly effective in EGFR-positive cancers.
A: The expression of the EGFR gene is regulated by various factors, including growth factors, cytokines, and transcription factors. In normal cells, EGFR expression is tightly controlled. However, in cancerous cells, EGFR can become overexpressed due to genetic alterations or amplification of the EGFR gene, leading to constitutive activation of its signaling pathways and uncontrolled cell growth.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The supplier of the Human EGFR Stable Cell Line-Ba/F3 has a strong reputation in the industry for providing high-quality cell lines and excellent customer service. Researchers can trust that they are receiving a reliable product that meets their experimental needs.
The Human EGFR Stable Cell Line-Ba/F3 is produced under strict standardization protocols, ensuring consistency and reproducibility across different batches of the cell line. This standardization is crucial for researchers to obtain reliable and comparable results.
The supplier offers customization services for the Human EGFR Stable Cell Line-Ba/F3, allowing researchers to modify the cell line to better suit their specific experimental requirements. This flexibility enables researchers to explore novel research questions and optimize their experimental designs.
The supplier provides excellent technical support to assist researchers in working with the Human EGFR Stable Cell Line-Ba/F3. This support includes guidance on cell culture techniques, experimental design, and data analysis.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
